Anemia
Volume 2019 (2019), Article ID 9242607, 4 pages
https://doi.org/10.1155/2019/9242607

Corrigendum

Corrigendum to “Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice”

António Robalo Nunes,¹ Ana Palricas Costa,² Sara Lemos Rocha,² and Ana Garcia de Oliveira²

¹Hospital de Dia de Imuno-Hemoterapia, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte (CHLN), Alameda das Linhas de Torres 117, 1769-001 Lisboa, Portugal
²Hospital de Dia de Imuno-Hemoterapia, Hospital de Santa Maria, CHLN, Avenida Prof. Egas Moniz, 1649-035 Lisboa, Portugal

Correspondence should be addressed to António Robalo Nunes; robalonunes@gmail.com

Received 8 October 2018; Accepted 9 October 2018; Published 1 January 2019

Copyright © 2019 António Robalo Nunes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice” [1], there were the following errors.

(i) In the Statistical Analysis section, “The computed OR were adjusted for age and pretreatment hemoglobin for the endpoints related to hemoglobin increase and for age and pretreatment transferrin saturation for the endpoint related to the increase of transferrin saturation” should be corrected to “The computed OR were adjusted for age and pre-treatment hemoglobin for the endpoints related with hemoglobin increase, and for age and pre-treatment ferritin for the endpoint related with the increase of transferrin saturation.”

(ii) There were multiple errors in the Efficacy Endpoints section. The corrected section is as follows.

“The primary (i.e., hemoglobin increase ≥2 g/dL) and secondary (i.e., hemoglobin increase ≥3 g/dL and transferrin saturation >20%) efficacy endpoints, following intravenous FCM treatment, are shown in Table 3. After 6 weeks, hemoglobin increase ≥2 g/dL was attained by 41% of all patients, 49% in the IDA group, 40% in the diseases of the digestive system group, 55% in the diseases of the genitourinary system group, 26% in the neoplasms group, and 29% in the diseases of the circulatory system group. Moreover, our analysis indicated that patients with IDA or diseases of the genitourinary system presented significant decreased odds of clinical failure (OR: 0.07, 95% CI 0.03-0.15 or OR: 0.46, 95% CI 0.25-0.87, respectively), whereas patients with diseases of the circulatory system showed about three times higher odds of clinical failure (OR: 3.34, 95% CI 1.31-8.98). Regarding cumulative FCM treatment dose, we found significant decreased odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.34, 95% CI 0.18-0.62) or 1001-3000 mg doses (OR: 0.19, 95% CI 0.07-0.49), compared to patients who received doses of 500 mg (Table 3).

Hemoglobin increase of ≥3 g/dL after 6 weeks after FCM dose was attained by 20% of all patients, 25% of the patients in the IDA group, 22% in the diseases of the digestive system group, 26% in the diseases of the genitourinary system group, 11% in the neoplasms group, and 16% in the diseases of the circulatory system group. Furthermore, our analysis indicated that patients with IDA presented significant lower odds of clinical failure (OR: 0.07, 95% CI 0.01-0.22). Concerning total FCM treatment dose, our analysis showed significant lower odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.36, 95% CI 0.12-0.92) or 1001-3000 mg doses (OR: 0.23, 95% CI 0.06-0.73), compared to patients who received doses of 500 mg (Table 3).

Finally, transferrin saturation >20% after 6 weeks after FCM dose was attained by 63% of all patients, 62% of patients in the IDA group, 69% of patients in the iron deficiency without anemia group, 63% in the diseases of the digestive system group, 68% in the diseases of the genitourinary system group, 67% in the neoplasms group, and 47% in the diseases of the circulatory system group. Our analysis indicated significant lower odds of clinical failure in patients who received doses ranging from 501 to 1000 mg (OR: 0.57, 95% CI 0.36-0.88) or 1001-3000 mg doses (OR: 0.25, 95% CI 0.10-0.55), compared to patients who received doses of 500 mg (Table 3).”

(iii) There were errors in Table 3. The corrected table is shown below.

(iv) In the Discussion section, “For patients with IDA, no differences in treatment efficacy were found for hemoglobin increase of ≥2 g/dL and transferrin saturation > 20%, compared with patients without IDA. However, we found a significant difference in hemoglobin increase of ≥3 g/dL” should be corrected to “For patients with IDA, no differences in treatment efficacy were found for transferrin saturation >20%, compared with patients without IDA. However, we found significant differences in both hemoglobin-related efficacy endpoints.”

Table 3: Odds ratio of clinical failure in primary and secondary efficacy endpoints for intravenous FCM treatment.

Hemoglobin increase ≥2 g/dL
Hemoglobin increase ≥3 g/dL
Transferrin saturation >20%

Characteristic
N
n (%)
OR (95% CI)
N
n (%)
OR (95% CI)
N
n (%)
OR (95% CI)

All
459
190 (41)
-
459
94 (20)
-
450
285 (63)
-

Male
101
35 (35)
1.7 (0.94-3.13)
101
20 (20)
1.01 (0.50-2.10)
98
54 (55)
1.45 (0.91-2.31)

Iron deficiency anemia
373
184 (49)
0.07 (0.03-0.15)
373
92 (25)
0.07 (0.01-0.22)
373
232 (62)
1.29 (0.77-2.23)

Iron deficiency without anemia
77
-
-
77
-
-
77
53 (69)
0.77 (0.45-1.30)

Diseases of the digestive system
199
79 (40)
0.88 (0.54-1.42)
199
43 (22)
0.57 (0.31-1.04)
195
123 (63)
0.95 (0.63-1.4)

Diseases of the genitourinary system
121
67 (55)
0.46 (0.25-0.87)
121
31 (26)
1.22 (0.59-2.54)
52
82 (68)
0.88 (0.52-1.48)

Neoplasms
47
12 (26)
2.19 (0.98-5.19)
47
5 (11)
1.63 (0.57-5.72)
45
30 (67)
0.70 (0.35-1.38)

Diseases of the circulatory system
38
11 (29)
3.34 (1.31-8.98)
38
6 (16)
2.1 (0.72-6.86)
38
18 (47)
1.82 (0.91-3.65)

Other diseases
54
21 (39)
0.94 (0.45-1.97)
54
9 (17)
1.12 (0.47-2.90)
52
32 (62)
1.13 (0.61-2.06)

Cumulative FCM treatment dose

500 mg
122
18 (15)
-
122
5 (4)
-
114
58 (51)
-

501–1000 mg
290
141 (49)
0.34 (0.18-0.62)
290
70 (24)
0.36 (0.12-0.92)
289
189 (65)
0.57 (0.36-0.88)

1001–3000 mg
47
31 (66)
0.19 (0.07-0.49)
47
19 (40)
0.23 (0.06-0.73)
47
38 (81)
0.25 (0.10-0.55)

Significant odds ratio in boldface.

CI: confidence interval; FCM: ferric carboxymaltose; N: total number of subjects; n: number of subjects achieving the endpoint; OR: odds ratio.

Only patients who had transferrin saturation <20% before treatment were considered for this endpoint. Therefore, all data presented for this endpoint only considers those subjects with iron deficiency.

Reference group: cumulative iron dose of 500 mg.

Supplementary Materials

The underlying patient-level data and a script with all the logistic regression models adjusted to generate the Odds Ratio and respective confidence intervals for Table 3 are included as Supplementary Materials. (Supplementary Materials)

References

A. R. Nunes, A. P. Costa, S. L. Rocha, and A. G. De Oliveira, “Efficacy and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency at a hospital outpatient clinic: A retrospective cohort study of real-world clinical practice,” Anemia, vol. 2017, Article ID 3106890, 7 pages, 2017.